搜尋

搜尋:
只搜尋:

總共找到: 109 項結果。

第 2 頁，共 6 頁

脊髓損傷排尿照護專區首頁

脊髓損傷者患者在台灣多是弱勢且隱性的病人族群。而這近二十多年來有賴健保制度的實行、各地脊髓損傷者協會陸續成立、與長期各地泌尿科醫師的義診、衛教與專業醫療照護下，病人漸漸能瞭解自身神經性膀胱的處理原則，且逐漸受到妥善的照顧，減少併發症，增進生活品質。
 
「台灣脊髓損傷排尿照護網」在2015年1月24日宣布成立，希望藉著國內各地區泌尿科醫師的共識，結合成為全國脊髓損傷者神經性膀胱照護網路。這些年我們除了持續進行全台灣各區的義診及衛教講座之外，透過「台灣脊髓損傷排尿照護網」四場專家會議的內容，經由專家共同整理並合力完成，將所有內容以英文撰寫，由郭漢崇醫師統整後，陸續發表於台灣泌尿科醫學會雜誌(Urol Sci)。 同時也將這些內容全文翻譯成中文集結成「台灣脊髓損傷神經性因下尿路功能障礙之臨床診療指引」，希望藉著此一診療指引，能夠協助國內泌尿科及復健科醫師，了解脊髓損傷病人的臨床需求及下尿路功能障礙，並且根據診療指引，使得照護脊髓損傷者排尿障礙的泌尿科醫師能有一致的共識及醫療行為，得以給全國脊髓損傷者的排尿照護有一共同而且適當的處置方式。
 
 
 
 
 

《脊時資訊》

《脊刻出發義診》

《脊時保健》

 

《脊管家APP》

脊管家app為脊損朋友提供風險評估及醫療資訊查詢等各項功能，歡迎使用行動裝置(手機或平板)點選下圖來安裝使用。所有文章衛教知識，均由花蓮慈濟醫院泌尿部醫護團隊編寫，或節錄《脊髓損傷排尿照護居家寶典》一書中的各項文章
 

 

 
 
脊管家APP操作說明

SCI義診花絮-20201220宜蘭脊損協會

      

義診花絮-109/12/20宜蘭縣脊髓損傷者協會

 回上一頁

 

 
 
 
 
 
 
 
 
 
 
 
 
 

vdtrc 專家會議(II)

      

   

 

 回上一頁

 
 
 
 
 
 

脊髓損傷者必做檢查

 
 

106年3月門診衛教活動，歡迎各位踴躍參與~

106年3月門診衛教活動，歡迎各位踴躍參與~~~~
時間 : 每週三，13:30~13:50
地點 : 泌尿部門診

攝護腺肥大 雷射手術治療



 
       攝護腺是在男性骨盆底最深處的一個器官，一般體積是20-30毫升，約是一個乒乓球大小。它本身是一個腺體，包圍著尿道，因此若產生增生肥大情形，常會造成尿道阻塞而致排尿障礙。攝護腺肥大是一種良性的增生，切確成因並不清楚，但已知與年齡、基因、雄性素、發炎、及肥胖等因素相關。

vdtrc 專家會議 (III)

      

   

 

 回上一頁

 
 
 
 
 
 

脊損傷友急救包

 

聯合畫展藝品活動-2024/05/04

 

 

 

 

 

 

 

 

 

活動日期：2024/05/04

活動地點：花蓮慈濟門診大廳

 

陳聖復 科主任

陳聖復醫師
醫師代碼 :15081

我要掛號

專   長

  • 老年排尿障礙、尿失禁、夜尿症
  • 小兒泌尿、包皮手術、隱睪症、精索靜脈曲張
  • 疝氣微創手術
  • 前列腺肥大微創手術
  • 尿路結石內視鏡微創治療、軟式輸尿管鏡
  • 泌尿腫瘤
  • 性功能障礙、男性更年期

現　職

  • 佛教慈濟醫療財團法人花蓮慈濟醫院泌尿部 神經性泌尿科 主任
  • 教育部部定助理教授
  • 慈濟大學醫學系專任助理教授

學　歷

  • 中國醫藥大學醫學系

經　歷

  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部 主治醫師
  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿科臨床研究醫師
  • 台大醫院泌尿部住院總醫師
  • 台大醫院泌尿部住院醫師

簡易介紹

  • 台灣泌尿科醫學會專科醫師
  • 台灣尿失禁防治協會會員
  • 台灣男性醫學會會員
  • 台灣泌尿科醫學會資訊及線上教育委員會委員
  • 台灣泌尿科醫學會小兒泌尿學委員會委員
  • 台灣泌尿科醫學會專科醫師出題委員

發表論文

  • Chen SF, Kuo HC.Urethral Sphincter Botulinum Toxin A Injection for Non-Spinal Cord Injured Patients with Voiding Dysfunction without Anatomical Obstructions: Which Patients Benefit Most? Toxins (Basel). 2023 Jan 17;15(2):8
  • Chen SF, Kuo HC. Management of spinal cord injury patients with neurogenic lower urinary tract dysfunction using minimally invasive and surgical therapies in Taiwan.Int Urol Nephrol. 2023 Nov 30. doi: 10.1007/s11255-023-03884-8.
  • Chen SF, Lee YK, Kuo HC. Satisfaction with Urinary Incontinence Treatments in Patients with Chronic Spinal Cord Injury J Clin Med. 2022 Oct; 11(19): 5864
  • Chen SF, Jiang YH, Chang JF, Kuo HC. Satisfaction with Detrusor OnabotulinumtoxinA Injections and Conversion to Other Bladder Management in Patients with Chronic Spinal Cord Injury. Toxins (Basel). 2022 Jan; 14(1): 35.
  • Chen SF, Chuang YC, Wang CC, Liao CH, Kuo HC. Therapeutic efficacy and cognitive adverse events of overactive bladder medication in patients with central nervous system Disorders-A cohort study.J Formos Med Assoc. 2022 Oct;121(10):2101-2108.
  • Chen SF, Peng CH, Kuo HC. Will detrusor acontractility recover after medical or surgical treatment? A longitudinal long-term urodynamic follow-up
    Neurourol Urodyn. 2021 Jan;40(1):228-236.doi: 10.1002/nau.24540. Epub 2020 Oct 14.
  • Jiang YH, Lee CL, Chen SF, Kuo HC. Therapeutic Effects of Urethral Sphincter Botulinum Toxin A Injection on Dysfunctional Voiding with Different Videourodynamic Characteristics in Non-Neurogenic Women.Toxins (Basel). 2021 May 19;13(5):362. doi: 10.3390/toxins13050362.PMID: 34069448
  • Jiang YH, Chen SF, Kuo HC. Frontiers in the Clinical Applications of Botulinum Toxin A as Treatment for Neurogenic Lower Urinary Tract Dysfunction.Int Neurourol J. 2020 Dec;24(4):301-312. doi: 10.5213/inj.2040354.177. Epub 2020 Dec 31.
  • Chen SF, Lee CL, Kuo HC. Change of Detrusor Contractility in Patients with and without Bladder Outlet Obstruction at Ten or More Years of follow-up. Scientific Reports. 2019 Dec 11;9(1):18887. doi: 10.1038/s41598-019-55386-2.
  • Chen SF, Kuo HC. Will repeated botulinum toxin A improve detrusor overactivity and bladder compliance in patients with chronic spinal cord injury? Tzu Chi Med J. 2020 Jul 29;33(2):101-107. doi: 10.4103/tcmj.tcmj_77_20. eCollection 2021 Apr-Jun.
  • Chen SF, Lee CL, Kuo HC. Changes in sensory proteins in the bladder urothelium of patients with chronic kidney disease and end-stage renal disease.Low Urin Tract Symptoms. 2019 Apr;11(2):O202-O208. doi: 10.1111/luts.12240. Epub 2018 Sep 9.
  • Chen SF, Jiang YH, Kuo HC. Single onabotulinumtoxinA 200U dose improved clinical symptoms but not urothelial dysfunction in neurogenic detrusor overactivity due to spinal cord injury. J Formos Med Assoc. 2018 Feb 23. pii: S0929-6646(17)30867-7. doi: 10.1016/j.jfma.2018.02.002.
  • Chen SF, Kuo HC.Therapeutic efficacy of low-dose (25 mg) mirabegron therapy for patients with mild to moderate overactive bladder symptoms due to central nervous system diseases.Low Urin Tract Symptoms. 2018 Jan 30. doi: 10.1111/luts.12215.
  • Chen SF, Jiang YH, Kuo HC. (2017, Oct) Urinary biomarkers in patients with detrusor underactivity with and without bladder function recovery.Int Urol Nephrol. 2017 Oct;49(10):1763-1770. doi: 10.1007/s11255-017-1666-z.
  • Chen SF, Chang CH, Kuo HC Clinical Efficacy and Changes of Urothelial Dysfunction after Repeated Detrusor Botulinum Toxin A Injections in Chronic Spinal Cord-Injured Bladder. Toxins (Basel).2016 May 30;8(6).
  • Chen SF, Chang CH, Kuo HC  Effect of detrusor botulinum toxin a injection on urothelial dysfunction in patients with chronic spinal cord injury: a clinical and immunohistochemistry study before and after treatment. Spinal Cord.2016 Oct;54(10):889-894
  • Chen SF, Kuo HC  Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity J Formos Med Assoc.2015 Jul;114(7):583-9
  • Liao CH, Chen SF, Kuo HC. Different number of intravesical onabotulinumtoxinA injections for patients with refractory detrusor overactivity do not affect treatment outcome: A prospective randomized comparative study.
    Neurourol Urodyn. 2015 Apr 24. doi: 10.1002/nau.22780
  • Chen SF, Chueh SC, Wang SM, Wu VC, Pu YS, Wu KD, Huang KH  Clinical outcomes in patients undergoing laparoscopic adrenalectomy for unilateral aldosterone producing adenoma: partial versus total adrenalectomy
    J Endourol.2014 Sep;28(9):1103-6
  • Chen SF, Kuo HC  Improvement in autonomic dysreflexia after detrusor onabotulinumtoxinA injections in patients with chronic spinal cord injuries
    Tzu Chi Medical Journal, Vol. 24, Issue 4, p201–204

國際論文演講

  • Sheng-Fu Chen, Hann-Chorng Kuo Effect of detrusor Botox injection on the urothelial dysfunction in chronic spinal cord injury bladders comparison among baseline, 3 months and 6 months (2014 EAU 歐洲泌尿科醫學會年會)
  • Sheng-Fu Chen / Huai-Ching Tai / Hong-Jeng Yu / Shih-Ping Liu; Yeong-Shiau Pu Are Lower Urinary Tract Symptoms in Women with Type 2 Diabetes Affected by Glycemic Control (2013 AUA 美國泌尿科醫學會年會)
  • Sheng-Fu Chen, Hann-Chorng Kuo Improvement in autonomic dysreflexia after detrusor onabotulinumtoxinA injections in patients with chronic spinal cord injuries (2013 AUA 美國泌尿科醫學會年會)
  •  Sheng-Fu Chen, Hann-Chorng Kuo  lack of consistent therapeutic effects of repeated 200 u onabotulinumtoxina detrusor injections on urinary incontinence in chronic spinal cord injured patients (2012 aua 美國泌尿科醫學會年會)

 

 

106年2月門診衛教活動，歡迎各位踴躍參與~

106年2月門診衛教活動，歡迎各位踴躍參與~~~~
時間 : 每週三，13:30~13:50
地點 : 泌尿部門診

前列腺肥大症的藥物與手術治療


 

        良性前列腺肥大是中年以上男性最常見的泌尿道生理變化，也常常被認為是中年及老年男人下尿路症狀的主要原因。大約到男性50歲左右有些前列腺便會逐漸的腫大，使得尿道阻力增加，因此會使得排尿時膀胱面臨著較大的尿道阻力而造成膀胱出口的症狀。

vdtrc 專家會議 (I)

      

   

 

 回上一頁

 
 
 
 
 
 
 
 
 
 
 

義診活動-2024/02/03花蓮義診

 

 

 

 

義診日期：2024/02/03

義診地點：花蓮國軍英雄館

 

張嘉峰 科主任

張嘉峰醫師

醫師代碼 :15068
我要掛號

專 長

  • 一般泌尿學
  • 尿路結石治療
  • 攝護腺肥大
  • 排尿障礙
  • 一般泌尿科手術
  • 生殖泌尿道感染
  • 男性不孕症

現 職

  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部 內視鏡泌尿科主任
  • 慈濟大學  部定講師
  • 台灣泌尿科醫學會 -- 功能性泌尿學委員會
  • 台灣泌尿科醫學會 -- 資訊及線上教育委員會委員
  • 台灣泌尿科醫學會 -- 專科醫師甄審委員會委員

學 歷

  • 慈濟大學醫學系

經 歷

  • 美國匹茲堡大學醫學院(University of Pittsburgh )進修排尿障礙及膀胱生理學
  • 2017年歐洲泌尿科醫學會研究醫師交換訓練計畫(fellowship exchange program)
  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部 內視鏡泌尿科代主任
  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部 主治醫師
  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部 臨床研究醫師
  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部 總醫師
  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部 住院醫師

獲獎及其他榮譽

  • 104年泌尿科專科醫師考試筆試全國第一名
  • 105年台灣泌尿科醫學會雜誌-會員基礎組論文獎
  • 105年台灣泌尿科醫學會論文獎-理事長論文獎
  • 106年慈濟醫學年會個人年輕最佳研究成果獎 第二名
  • 107年慈濟醫學年會個人年輕最佳研究成果獎 第一名

著 作 / 論文 相關

【2013】
  • Adding Cyclooxygenase-2 inhibitor to alpha blocker for patients with benign prostate hyperplasia and elevated serum prostate specific antigen could not improve prostate biopsy detection rate but improve lower urinary tract symptoms. Jhang JF, Jiang YH, Kuo HC. Int J Clin Pract. 2013 Dec;67(12):1327-33 (SCI)
  • Transurethral Incision of the bladder neck improves voiding efficiency in female patients with detrusor underactivity. Jhang JF, Jiang YH, Kuo HC. Int Urogynecol J.  2014 May;25(5):671-6.  (SCI)
  • Down Regulation of Vascular Endothelial Growth Factor Is Associated With Decreased Inflammation After Intravesical OnabotulinumtoxinA Injections Combined With Hydrodistention for Patients With Interstitial Cystitis-Clinical Results and Immunohistochemistry Analysis. Peng CH, Jhang JF, Shie JH, Kuo HC. Urology. 2013 Dec ;82(6):1452.e1-6. (SCI)
  • Severity of lower urinary tract symptoms reflects different composition of bladder storage dysfunction and bladder outlet obstruction in men with symptomatic benign prostatic hyperplasia. Jia-Fong Jhang, Chun-Hou Liao, Hann-Chorng Kuo. Int J Clin Pract. 2014 Jun;68(6):743-8. (SCI)
  • Characteristics and electrocauterization of Hunner's lesions associated with bladder pain syndrome   Urological Science, Volume 24, Issue 2, June 2013, Pages 51-55. Jia-Fong Jhang, Yung-Hsiang Hsu, Hann-Chorng Kuo
【2014】
  • Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. Jia-Fong Jhang, Hann-Chorng Kuo. Int J Urol 2014 Apr;21 Suppl 1:49-55 (SCI)
  • Elevated Serum Immunoglobulin E May Be Associated to the Development of Ketamine Cystitis. Jhang JF, Hsu YH, Jiang YH, Kuo HC. J Urol. 2014 Oct;192(4):1249-56 (SCI)
【2015】
  • Possible Pathophysiology of Ketamine-Related Cystitis and associated Treatment Srategies. Jhang JF, Hsu YH, Kuo HC. Int J Urol. 2015 Sep;22(9):816-25. (SCI)
  • Novel Treatment of Chronic Bladder Pain Syndrome and Other Pelvic Pain Disorders by OnabotulinumtoxinA Injection. Jhang JF, Kuo HC. Toxins (Basel). 2015 Jun 18;7(6):2232-50 (SCI)
  • Role of serum immunoglobulin E in patients with interstitial cystitis/bladder pain syndrome. Jhang JF, Kuo HC. Urological Science 26 (2015) 202-205
  • Long-term follow up and predictive factors for successful outcome of transurethral incision of the bladder neck in women with detrusor underactivity. Jhang JF, Jiang YH, Lee CL, Kuo HC. J Formos Med Assoc. 2015 Sep 12. pii: S0929-6646(15)00307-1 (SCI)
【2016】
  • The Role of Immunoglobulin E in the Pathogenesis of Ketamine Related Cystitis and Ulcerative Interstitial Cystitis – an Immunohistochemical Study. Jhang JF, Hsu YH, Jiang YH, Kuo HC. Pain physician 2016 19(4):E581-7.
  • Patient characteristics for different therapeutic strategies in the management ketamine cystitis. Jhang JF, Birder LA, Chancellor MB, Kuo HC. Neurourol Urodyn. 2016 Mar 21. (SCI)
  • Revisiting the Role of Potassium Sensitivity Testing and Cystoscopic Hydrodistention for the Diagnosis of Interstitial Cystitis. Jiang YH, Jhang JF, Kuo HC. PLoS One. 2016 Mar 21;11(3):e0151692. (SCI)
  • Urothelial functional protein and sensory receptors in patients with interstitial cystitis/bladder pain syndrome with and without Hunner’s lesion. Jhang JF, Hsu YH, Kuo HC. Urology 2016 Dec;98:44-49 (SCI)
【2017】
  • Bladder dysfunction in 2016: New insights into interstitial cystitis and chronic pelvic pain syndromes. Jhang JF, Kuo HC. Nat Rev Urol. 2017 Feb;14(2):69-70. (SCI)
  • Pathomechanism of Interstitial Cystitis/Bladder Pain Syndrome and Mapping the Heterogeneity of Disease. Jhang JF, Kuo HC. Int Neurourol J. 2016 Nov;20(Suppl 2):S95-104. Epub 2016 Nov 22 (SCI)
  • Clinical Outcome of Augmentation Enterocystoplasty for Patients with Ketamine-induced Cystitis. Lee YK, Jhang JF, Kuo HC. Pain Physician. 2017 Mar;20(3):E431-E436.(SCI)
  • Recent advances in recurrent urinary tract infection from pathogenesis and biomarkers to prevention. Jhang JF, Kuo HC.Ci Ji Yi Xue Za Zhi. 2017 Jul-Sep;29(3):131-137.Review (SCI)
  • Videourodynamic factors predictive of successful onabotulinumtoxinA urethral sphincter injection for neurogenic or non-neurogenic detrusor underactivity. Jiang YH, Jhang JF, Chen SF, Kuo HC.Low Urin Tract Symptoms. 2017 Oct 11. doi: 10.1111/luts.12195. [Epub ahead of print] (SCI)
  • Repeated intravesical injections of platelet-rich plasma are effective in the treatment of interstitial cystitis: a case control pilot study. Jhang JF, Wu SY, Lin TY, Kuo HC.Low Urin Tract Symptoms. 2017 Dec 19. doi: 10.1111/luts.12212. [Epub ahead of print] (SCI)
  • Current pharmacological and surgical treatment of underactive bladder. Jiang YH, Lee CL, Jhang JF, Kuo HC.Ci Ji Yi Xue Za Zhi. 2017 Oct-Dec;29(4):187-191. doi: 10.4103/tcmj.tcmj_122_17. Review. (SCI)
【2018】
  • Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. Jiang YH, Jhang JF, Lee CL, Kuo HC.Neurourol Urodyn. 2018 Apr;37(4):1467-1473. doi: 10.1002/nau.23475. (SCI)
  • Histopathological characteristics of ketamine-associated uropathy and their clinical association. Jhang JF, Hsu YH, Jiang YH, Lee CL, Kuo HC. Neurourol Urodyn. 2018 Feb 14. doi: 10.1002/nau.23514. [Epub ahead of print] (SCI)
  • Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy. Chen YC, Jhang JF, Hsu YH, Kuo HC. Low Urin Tract Symptoms. 2018 Mar 11. doi: 10.1111/luts.12221. [Epub ahead of prin] (SCI)
  • Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC. J Urol. 2018 Apr 11. pii: S0022-5347(18)42926-6. doi: 10.1016/j.juro.2018.03.133. [Epub ahead of print] (SCI)
  • Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Jiang YH, Chen SF, Jhang JF, Kuo HC. Neurourol Urodyn. 2018 May 24. doi: 10.1002/nau.23714. [Epub ahead of print] (SCI)
  • Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. PLoS One. 2018 Jun 7;13(6):e0198816. doi: 10.1371/journal.pone.0198816. eCollection 2018.(SCI)
  • Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. Jhang JF, Kuo HC. Toxins (Basel). 2018 Jun 26;10(7). pii: E260. doi: 10.3390/toxins10070260. Review. (SCI)
  • Comparative study of efficacy and safety between bladder body and trigonal intravesical onabotulinumtoxina injection in the treatment of interstitial cystitis refractory to conventional treatment-A prospective, randomized, clinical trial. Jiang YH, Jhang JF, Lee CL, Kuo HC.Neurourol Urodyn. 2018 Apr;37(4):1467-1473. doi: 10.1002/nau.23475. (SCI)
  • Histopathological characteristics of ketamine-associated uropathy and their clinical association. Jhang JF, Hsu YH, Jiang YH, Lee CL, Kuo HC. Neurourol Urodyn. 2018 Feb 14. doi: 10.1002/nau.23514. [Epub ahead of print] (SCI)
  • Vascular fibrinoid necrosis in the urinary bladder of ketamine abusers: A new finding that may provide a clue to the pathogenesis of ketamine-induced vesicopathy. Chen YC, Jhang JF, Hsu YH, Kuo HC. Low Urin Tract Symptoms. 2018 Mar 11. doi: 10.1111/luts.12221. [Epub ahead of prin] (SCI)
  • Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome. Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC. J Urol. 2018 Apr 11. pii: S0022-5347(18)42926-6. doi: 10.1016/j.juro.2018.03.133. [Epub ahead of print] (SCI)
  • Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity. Jiang YH, Chen SF, Jhang JF, Kuo HC. Neurourol Urodyn. 2018 May 24. doi: 10.1002/nau.23714. [Epub ahead of print] (SCI)
  • Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. PLoS One. 2018 Jun 7;13(6):e0198816. doi: 10.1371/journal.pone.0198816. eCollection 2018.(SCI)
  • Novel Applications of OnabotulinumtoxinA in Lower Urinary Tract Dysfunction. Jhang JF, Kuo HC. Toxins (Basel). 2018 Jun 26;10(7). pii: E260. doi: 10.3390/toxins10070260. Review. (SCI)
  • Epstein-Barr Virus as a Potential Etiology of Persistent Bladder Inflammation in Human Interstitial Cystitis/Bladder Pain Syndrome.Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC.J Urol. 2018 Sep;200(3):590-596. doi: 10.1016/j.juro.2018.03.133. Epub 2018 Apr 11.PMID: 29653163
  • Therapeutic effect of urethral sphincter onabotulinumtoxinA injection for urethral sphincter hyperactivity.Jiang YH, Chen SF, Jhang JF, Kuo HC.Neurourol Urodyn. 2018 Nov;37(8):2651-2657. doi: 10.1002/nau.23714. Epub 2018 May 24.PMID: 29797345

【2019】

【2020】

【2021】

【2022】

【2023】

【2024】

 

 

 

 

106年1月門診衛教活動，歡迎大家踴躍參與~

106年1月門診衛教活動，歡迎各位踴躍參與~~~~
時間 : 每週三，13:30~13:50
地點 : 泌尿部門診

前列腺肥大微創手術-雷射治療



 
        前言：男性到了中年之後，前列腺從三十五歲就開始退化，五十歲以上的男性，有一半以上會有前列腺肥大的問題，成因可能與年齡的增長、男性荷爾蒙變化有關，屬於良性纖維瘤的增生，而隨著年紀增加則會越來越嚴重。

vdtrc 專家會議

      

110年8月1日

Taiwan Neurogenic Voiding Dysfunction Bladder Care Team Symposium (I)

110年11月

Taiwan Neurogenic Voiding Dysfunction Bladder Care Team Symposium (II)

111年2月

Taiwan Neurogenic Voiding Dysfunction Bladder Care Team Symposium (III)

111年5月

Taiwan Neurogenic Voiding Dysfunction Bladder Care Team Symposium (IV)
 
 
 
 
 

義診活動-2023/11/26宜蘭義診

 

 

 

 

義診日期：2023/11/26

義診地點：宜蘭

 

李政霖 醫師

李政霖醫師
醫師代碼 :15066
我要掛號

專 長

  • 尿路結石治療
  • 攝護腺肥大
  • 泌尿腫瘤
  • 老人泌尿科
  • 排尿障礙

現 職

  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部主治醫師

學 歷

  • 澳洲塔斯馬尼亞大學

經 歷

  • 佛教慈濟醫療財團法人花蓮慈濟醫院 泌尿部病房主任
  • 佛教慈濟醫療財團法人花蓮慈濟醫院泌尿部 臨床研究醫師
  • 佛教慈濟醫療財團法人花蓮慈濟醫院泌尿部 總醫師
  • 佛教慈濟醫療財團法人花蓮慈濟醫院泌尿部 住院醫師

著 作 / 論文 相關

  • Lee CL, Kuo HC. Intravescial botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician 2013; 16: 109-16
  • Lee CL, Jiang YH, Kuo HC: Increased apoptosis and suburothelial inflammation in patients with ketamine-related cystitis: a comparison with non-ulcerative interstitial cystitis and controls. BJU Int. 2013 Dec;112(8):1156-62
  • Lee CL, Su BC, Kuo HC. The dreadful and the deadly erection-Malignant priapism from renal cell carcinoma. Urol Sci 2014; 25:152-4.
  • Lee CL, Peng CH, Kuo HC. Therapeutic effects and predictive factors for successful intravesical hyaluronic acid instillation on interstitial cystitis/bladder pain syndrome. Urol Sci2015; 26:125-30.
  • Lee CL, Kuo HC. Long-term efficacy and safety of repeated intravescial onabotulinumtoxinA injections plus hydrodistention in the treatment of interstitial cystitis/ bladder pain syndrome. Toxins 2015; 7:4283-93.
  • Lee CL, Kuo HC. Videourodynamic analysis in men with lower urinary tract symptoms: correlation between age and prostate size with lower urinary tract dysfunction. Urol Sci 2016; 27:21-5.
  • Lee CL, Kuo HC. Botulinum toxin A treatment for lower urinary tract symptoms/ benign prostatic hyperplasia. Urol Sci 2017; 28:119-22.
  • Lee CL, Kuo HC. Current consensus and controversy on the diagnosis of male lower urinary tract symptoms/benign prostatic hyperplasia. Tzu Chi Med J 2017; 29:6-11. (Review)
  • Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms – current concept. Tzu Chi Med J 2017; 29:79-83. (Review)
  • Lee CL, Kuo HC. Tailoring medication for lower urinary tract symptoms in men based on International Prostate Symptom Score voiding to storage ratio. Urology 2018; 120:30-35.
  • Lee CL, Kuo HC. Efficacy and safety of mirabegron, a β-3 adrenoceptor agonist, in patients with detrusor hyperactivity and impaired contractility. Low Urin Tract Symptoms 2019; 11:O93-7.
  • Lee CL, Kuo HC. Male patients with higher nocturnal urinary frequency episodes are more likely to benefit from alpha-blocker therapy for bothersome nocturia. Low Urin Tract Symptoms 2019; 11:O174-9.
  • Lee CL, Ong HL, Kuo HC. Therapeutic efficacy of mirabegron 25 mg monotherapy in patients with nocturia-predominant hypersensitive. Tzu Chi Med J 2020; 32:30-5.
  • Lee CL, Kuo HC. Treating overactive bladder symptoms after transurethral prostatic surgery for benign prostatic hyperplasia – Which medication to choose? Tzu Chi Med J 2023; 35:312-316.

 

 

Copyright © 2017 花蓮慈濟醫學中心. 版權所有. 地址：花蓮市中央路三段707號　連絡電話：03-8561825